Skip to main content

Advertisement

SpringerLink
Log in

Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality

  • Review
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

Morbidity and mortality in patients with moderate to severe community-acquired pneumonia (CAP) is a global problem, and CAP is a leading cause of death due to infectious diseases. Prompt initiation of expanded-spectrum antimicrobials is essential for the prevention of unnecessary mortality and complications in patients, particularly in the elderly and other at-risk populations, and the treatment decisions made by practitioners have important implications for healthcare systems when hospitalization is required. Empirical antimicrobial treatment and the appropriate management of CAP patients will initially require the proper assessment of severity and patient risk for increased mortality, as well as risk factors for difficult-to-treat bacteria. This review will examine risk factors and scoring systems that may be predictive of moderate to severe CAP, which is often linked to increased risk of mortality. Understanding and recognizing potential risk factors will allow practitioners to proactively identify patients at the highest risk for severe illness or complications, thereby, guiding site-of-care decisions, as well as the choices for empiric antibiotic regimens. The decision to hospitalize a patient with CAP should include not only a clinical perspective and laboratory and radiographic findings, but also at least one objective tool of risk assessment, all in combination with sound clinical judgment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R (1998) The cost of treating community-acquired pneumonia. Clin Ther 20(4):820–837

    PubMed  CAS  Google Scholar 

  2. Schnoor M, Hedicke J, Dalhoff K, Raspe H, Schäfer T (2007) Approaches to estimate the population-based incidence of community acquired pneumonia. J Infect 55(3):233–239

    PubMed  Google Scholar 

  3. Viegi G, Pistelli R, Cazzola M, Falcone F, Cerveri I, Rossi A, Ugo Di Maria G (2006) Epidemiological survey on incidence and treatment of community acquired pneumonia in Italy. Respir Med 100(1):46–55

    PubMed  Google Scholar 

  4. Dias J, Correia AM, Queirós L (2007) Community-acquired pneumonia and influenza hospitalisations in northern Portugal, 2000–2005. Euro Surveill 12(7):E13–E14

    PubMed  CAS  Google Scholar 

  5. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, Kapoor WN (1996) Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA 275(2):134–141

    PubMed  CAS  Google Scholar 

  6. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ (2000) Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 31(2):347–382

    PubMed  CAS  Google Scholar 

  7. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, Coley CM, Marrie TJ, Kapoor WN (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336(4):243–250

    PubMed  CAS  Google Scholar 

  8. Pinner RW, Teutsch SM, Simonsen L, Klug LA, Graber JM, Clarke MJ, Berkelman RL (1996) Trends in infectious diseases mortality in the United States. JAMA 275(3):189–193

    PubMed  CAS  Google Scholar 

  9. Welte T, Marre R, Suttorp N (2006) What is new in the treatment of community-acquired pneumonia? Med Klin (Munich) 101(4):313–320

    Google Scholar 

  10. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, Angus DC (2003) Pneumonia: still the old man’s friend? Arch Intern Med 163(3):317–323

    PubMed  Google Scholar 

  11. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F (2004) Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 164(5):502–508

    PubMed  Google Scholar 

  12. Monge V, San-Martín VM, González A (2001) The burden of community-acquired pneumonia in Spain. Eur J Public Health 11(4):362–364

    PubMed  CAS  Google Scholar 

  13. Grassi V, Romanelli G (2006) Pneumonia: state-of-art and perspectives. Recenti Prog Med 97(12):697–703

    PubMed  Google Scholar 

  14. Welte T (2007) Treatment of community acquired pneumonia. Internist (Berl) 48(5):476, 478–480, 482–484 passim

    CAS  Google Scholar 

  15. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C (2003) Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 37(11):1405–1433

    PubMed  Google Scholar 

  16. Lode HM (2007) Managing community-acquired pneumonia: a European perspective. Respir Med 101(9):1864–1873

    PubMed  Google Scholar 

  17. Farr BM, Bartlett CL, Wadsworth J, Miller DL (2000) Risk factors for community-acquired pneumonia diagnosed upon hospital admission. British Thoracic Society Pneumonia Study Group. Respir Med 94(10):954–963

    PubMed  CAS  Google Scholar 

  18. Kohlhammer Y, Schwartz M, Raspe H, Schäfer T (2005) Risk factors for community acquired pneumonia (CAP). A systematic review. Dtsch Med Wochenschr 130(8):381–386

    PubMed  CAS  Google Scholar 

  19. Gutiérrez F, Masiá M, Mirete C, Soldán B, Rodríguez JC, Padilla S, Hernández I, Royo G, Martin-Hidalgo A (2006) The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 53(3):166–174

    PubMed  Google Scholar 

  20. Kaplan V, Angus DC, Griffin MF, Clermont G, Scott Watson R, Linde-Zwirble WT (2002) Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 165(6):766–772

    PubMed  Google Scholar 

  21. Riquelme R, Torres A, El-Ebiary M, de la Bellacasa JP, Estruch R, Mensa J, Fernández-Solá J, Hernández C, Rodriguez-Roisin R (1996) Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 154(5):1450–1455

    PubMed  CAS  Google Scholar 

  22. From S, Targowski T (2002) The risk factors of death in community-acquired pneumonia. Pol Merkur Lekarski 12(72):455–457

    PubMed  Google Scholar 

  23. Cabré M, Serra-Prat M, Bolíbar I, Pallarés R (2006) Prognostic factors of community acquired pneumonia in very old patients. Med Clin (Barc) 127(6):201–205

    Google Scholar 

  24. Niederman MS, Ahmed QA (2003) Community-acquired pneumonia in elderly patients. Clin Geriatr Med 19(1):101–120

    PubMed  Google Scholar 

  25. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH (2007) Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 51(10):3568–3573

    PubMed  CAS  Google Scholar 

  26. Kothe H, Bauer T, Marre R, Suttorp N, Welte T, Dalhoff K (2008) Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. Eur Respir J 32(1):139–146

    PubMed  CAS  Google Scholar 

  27. Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R, Manresa F, Gudiol F (2007) Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med 167(13):1393–1399

    PubMed  Google Scholar 

  28. Ortqvist A (1990) Prognosis in community-acquired pneumonia requiring treatment in hospital. Importance of predisposing and complicating factors, and of diagnostic procedures. Scand J Infect Dis Suppl 65:1–62

    PubMed  CAS  Google Scholar 

  29. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A (2008) A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest 133:610–617

    PubMed  Google Scholar 

  30. Angele MK, Frantz MC, Chaudry IH (2006) Gender and sex hormones influence the response to trauma and sepsis: potential therapeutic approaches. Clinics (Sao Paulo) 61(5):479–488

    Google Scholar 

  31. Zellweger R, Wichmann MW, Ayala A, Stein S, DeMaso CM, Chaudry IH (1997) Females in proestrus state maintain splenic immune functions and tolerate sepsis better than males. Crit Care Med 25(1):106–110

    PubMed  CAS  Google Scholar 

  32. Schröder J, Kahlke V, Book M, Stüber F (2000) Gender differences in sepsis: genetically determined? Shock 14(3):307–310

    PubMed  Google Scholar 

  33. Mortensen EM, Cornell J, Whittle J (2004) Racial variations in processes of care for patients with community-acquired pneumonia. BMC Health Serv Res 4(1):20

    PubMed  Google Scholar 

  34. Oliver MN, Stukenborg GJ, Wagner DP, Harrell FE Jr, Kilbridge KL, Lyman JA, Einbinder J, Connors AF Jr (2004) Comorbid disease and the effect of race and ethnicity on in-hospital mortality from aspiration pneumonia. J Natl Med Assoc 96(11):1462–1469

    PubMed  Google Scholar 

  35. Carbon C (2001) Optimal treatment strategies for community-acquired pneumonia: high-risk patients (geriatric and with comorbidity). Chemotherapy 47(Suppl 4):19–25, discussion 26–27

    PubMed  CAS  Google Scholar 

  36. O’Meara ES, White M, Siscovick DS, Lyles MF, Kuller LH (2005) Hospitalization for pneumonia in the Cardiovascular Health Study: incidence, mortality, and influence on longer-term survival. J Am Geriatr Soc 53(7):1108–1116

    PubMed  Google Scholar 

  37. Almirall J, Bolíbar I, Balanzó X, González CA (1999) Risk factors for community-acquired pneumonia in adults: a population-based case–control study. Eur Respir J 13(2):349–355

    PubMed  CAS  Google Scholar 

  38. Almirall J, Bolíbar I, Serra-Prat M, Roig J, Hospital I, Carandell E, Agustí M, Ayuso P, Estela A, Torres A (2008) New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31:1274–1284

    PubMed  CAS  Google Scholar 

  39. Schnoor M, Klante T, Beckmann M, Robra BP, Welte T, Raspe H, Schäfer T (2007) Risk factors for community-acquired pneumonia in German adults: the impact of children in the household. Epidemiol Infect 135(8):1389–1397

    PubMed  CAS  Google Scholar 

  40. Marrie TJ, Shariatzadeh MR (2007) Community-acquired pneumonia requiring admission to an intensive care unit: a descriptive study. Medicine (Baltimore) 86(2):103–111

    Google Scholar 

  41. Pifarre R, Falguera M, Vicente-de-Vera C, Nogues A (2007) Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 101(10):2139–2144

    PubMed  Google Scholar 

  42. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, Benítez Moya JM, Ruiz-Manzano J, Rodríguez de Castro F, Blanquer J, Pérez D, Puzo C, Sánchez Gascón F, Gallardo J, Alvarez C, Molinos L (2004) Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax 59(11):960–965

    PubMed  Google Scholar 

  43. Restrepo MI, Mortensen EM, Pugh JA, Anzueto A (2006) COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28(2):346–351

    PubMed  CAS  Google Scholar 

  44. Rello J, Rodriguez A, Torres A, Roig J, Sole-Violan J, Garnacho-Montero J, de la Torre MV, Sirvent JM, Bodi M (2006) Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27(6):1210–1216

    PubMed  CAS  Google Scholar 

  45. Fujiki R, Kawayama T, Ueyama T, Ichiki M, Aizawa H (2007) The risk factors for mortality of community-acquired pneumonia in Japan. J Infect Chemother 13(3):157–165

    PubMed  Google Scholar 

  46. Klare B, Kubini R, Ewig S (2002) Risk factors for pneumonia in patients with cardiovascular diseases. Pneumologie 56(12):781–788

    PubMed  CAS  Google Scholar 

  47. Ruiz M, Ewig S, Torres A, Arancibia F, Marco F, Mensa J, Sanchez M, Martinez JA (1999) Severe community-acquired pneumonia. Risk factors and follow-up epidemiology. Am J Respir Crit Care Med 160(3):923–929

    PubMed  CAS  Google Scholar 

  48. Paganin F, Lilienthal F, Bourdin A, Lugagne N, Tixier F, Génin R, Yvin JL (2004) Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 24(5):779–785

    PubMed  CAS  Google Scholar 

  49. Fernández-Solá J, Junqué A, Estruch R, Monforte R, Torres A, Urbano-Márquez A (1995) High alcohol intake as a risk and prognostic factor for community-acquired pneumonia. Arch Intern Med 155(15):1649–1654

    PubMed  Google Scholar 

  50. Falguera M, Pifarre R, Martin A, Sheikh A, Moreno A (2005) Etiology and outcome of community-acquired pneumonia in patients with diabetes mellitus. Chest 128(5):3233–3239

    PubMed  Google Scholar 

  51. Kornum JB, Thomsen RW, Riis A, Lervang HH, Schønheyder HC, Sørensen HT (2007) Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 30(9):2251–2257

    PubMed  Google Scholar 

  52. Genné D, Sommer R, Kaiser L, Saaïdia A, Pasche A, Unger PF, Lew D (2006) Analysis of factors that contribute to treatment failure in patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 25(3):159–166

    PubMed  Google Scholar 

  53. van Eeden SF, Coetzee AR, Joubert JR (1988) Community-acquired pneumonia—factors influencing intensive care admission. S Afr Med J 73(2):77–81

    PubMed  Google Scholar 

  54. Luna CM, Famiglietti A, Absi R, Videla AJ, Nogueira FJ, Fuenzalida AD, Gené RJ (2000) Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 118(5):1344–1354

    PubMed  CAS  Google Scholar 

  55. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ (2008) Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 46(4):550–556

    PubMed  Google Scholar 

  56. Peach H, Barnett N (2001) Does smoking contribute to community acquired pneumonia? Aust Fam Physician 30(1):10

    PubMed  CAS  Google Scholar 

  57. Almirall J, González CA, Balanzó X, Bolíbar I (1999) Proportion of community-acquired pneumonia cases attributable to tobacco smoking. Chest 116(2):375–379

    PubMed  CAS  Google Scholar 

  58. Inoue Y, Koizumi A, Wada Y, Iso H, Watanabe Y, Date C, Yamamoto A, Kikuchi S, Inaba Y, Toyoshima H, Tamakoshi A (2007) Risk and protective factors related to mortality from pneumonia among middleaged and elderly community residents: the JACC Study. J Epidemiol 17(6):194–202

    PubMed  Google Scholar 

  59. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG (2007) Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44(Suppl 2):S27–S72

    PubMed  CAS  Google Scholar 

  60. Ewig S, de Roux A, Bauer T, García E, Mensa J, Niederman M, Torres A (2004) Validation of predictive rules and indices of severity for community acquired pneumonia. Thorax 59(5):421–427

    PubMed  CAS  Google Scholar 

  61. España PP, Capelastegui A, Gorordo I, Esteban C, Oribe M, Ortega M, Bilbao A, Quintana JM (2006) Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med 174(11):1249–1256

    PubMed  Google Scholar 

  62. Gil DR, Undurraga PA, Saldías PF, Jiménez PP, Barros MM (2006) Prognostic factors and outcome of community-acquired pneumonia in hospitalized adult patients. Rev Med Chil 134(11):1357–1366

    Google Scholar 

  63. [No authors listed] (1987) Community-acquired pneumonia in adults in British hospitals in 1982–1983: a survey of aetiology, mortality, prognostic factors and outcome. The British Thoracic Society and the Public Health Laboratory Service. Q J Med 62(239):195–220

    Google Scholar 

  64. Raz R, Dyachenko P, Levy Y, Flatau E, Reichman N (2003) A predictive model for the management of community-acquired pneumonia. Infection 31(1):3–8

    PubMed  CAS  Google Scholar 

  65. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, Etienne J (2007) Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton–Valentine leukocidin. Clin Infect Dis 45(3):315–321

    PubMed  Google Scholar 

  66. Hedlund JU, Ortqvist AB, Kalin ME, Granath F (1993) Factors of importance for the long term prognosis after hospital treated pneumonia. Thorax 48(8):785–789

    PubMed  CAS  Google Scholar 

  67. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5):377–382

    PubMed  CAS  Google Scholar 

  68. Chalmers JD, Singanayagam A, Murray MP, Hill AT (2008) Prior statin use is associated with improved outcomes in community-acquired pneumonia. Am J Med 121(11):1002–1007

    PubMed  CAS  Google Scholar 

  69. Ernst P, Gonzalez AV, Brassard P, Suissa S (2007) Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176(2):162–166

    PubMed  CAS  Google Scholar 

  70. Woodhead M (2003) Assessment of illness severity in community acquired pneumonia: a useful new prediction tool? Thorax 58(5):371–372

    PubMed  CAS  Google Scholar 

  71. Capelastegui A, España PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, Bilbao A (2006) Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J 27(1):151–157

    PubMed  CAS  Google Scholar 

  72. Bauer TT, Ewig S, Marre R, Suttorp N, Welte T (2006) CRB-65 predicts death from community-acquired pneumonia. J Intern Med 260(1):93–101

    PubMed  CAS  Google Scholar 

  73. Ewig S, Welte T (2008) CRB-65 for the assessment of pneumonia severity: who could ask for more? Thorax 63(8):665–666

    PubMed  Google Scholar 

  74. Chalmers JD, Singanayagam A, Hill AT (2008) Systolic blood pressure is superior to other haemodynamic predictors of outcome in community acquired pneumonia. Thorax 63(8):698–702

    PubMed  CAS  Google Scholar 

  75. Nathwani D, Morgan M, Masterton RG, Dryden M, Cookson BD, French G, Lewis D (2008) Guidelines for UK practice for the diagnosis and management of methicillin-resistant Staphylococcus aureus (MRSA) infections presenting in the community. J Antimicrob Chemother 61(5):976–994

    PubMed  CAS  Google Scholar 

  76. Niederman MS, Bass JB Jr, Campbell GD, Fein AM, Grossman RF, Mandell LA, Marrie TJ, Sarosi GA, Torres A, Yu VL (1993) Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society. Medical Section of the American Lung Association. Am Rev Respir Dis 148(5):1418–1426

    PubMed  CAS  Google Scholar 

  77. Niederman MS (2001) Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Med Clin North Am 85(6):1493–1509

    PubMed  CAS  Google Scholar 

  78. Charles PG, Wolfe R, Whitby M, Fine MJ, Fuller AJ, Stirling R, Wright AA, Ramirez JA, Christiansen KJ, Waterer GW, Pierce RJ, Armstrong JG, Korman TM, Holmes P, Obrosky DS, Peyrani P, Johnson B, Hooy M, Grayson ML (2008) SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis 47(3):375–384

    PubMed  Google Scholar 

  79. Chalmers JD, Singanayagam A, Hill AT (2008) Predicting the need for mechanical ventilation and/or inotropic support for young adults admitted to the hospital with community-acquired pneumonia. Clin Infect Dis 47(12):1571–1574

    PubMed  Google Scholar 

  80. Yandiola PP, Capelastegui A, Quintana J, Diez R, Gorordo I, Bilbao A, Zalacain R, Menendez R, Torres A (2009) Prospective comparison of severity scores for predicting clinically relevant outcomes for patients hospitalized with community-acquired pneumonia. Chest 135(6):1572–1579

    PubMed  Google Scholar 

  81. Krüger S, Papassotiriou J, Marre R, Richter K, Schumann C, von Baum H, Morgenthaler NG, Suttorp N, Welte T (2007) Pro-atrial natriuretic peptide and pro-vasopressin to predict severity and prognosis in community-acquired pneumonia: results from the German competence network CAPNETZ. Intensive Care Med 33(12):2069–2078

    PubMed  Google Scholar 

  82. Krüger S, Ewig S, Marre R, Papassotiriou J, Richter K, von Baum H, Suttorp N, Welte T (2008) Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Respir J 31(2):349–355

    PubMed  Google Scholar 

  83. Huang DT, Weissfeld LA, Kellum JA, Yealy DM, Kong L, Martino M, Angus DC (2008) Risk prediction with procalcitonin and clinical rules in community-acquired pneumonia. Ann Emerg Med 52(1):48–58

    PubMed  Google Scholar 

  84. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A (2008) Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 63(5):447–452

    PubMed  Google Scholar 

  85. Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, Martínez A, Esquinas C, Ramirez P, Torres A (2009) Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 64(7):587–591

    PubMed  Google Scholar 

  86. Huang DT, Angus DC, Kellum JA, Pugh NA, Weissfeld LA, Struck J, Delude RL, Rosengart MR, Yealy DM (2009) Midregional proadrenomedullin as a prognostic tool in community-acquired pneumonia. Chest 136(3):823–831

    PubMed  CAS  Google Scholar 

  87. Krüger S, Ewig S, Giersdorf S, Hartmann O, Suttorp N, Welte T; German Competence Network for the Study of Community Acquired Pneumonia (CAPNETZ) Study Group (2010) Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: results from the German Competence Network, CAPNETZ. Am J Respir Crit Care Med 182(11):1426–1434

    PubMed  Google Scholar 

  88. Krüger S, Ewig S, Kunde J, Hartmann O, Suttorp N, Welte T; CAPNETZ Study Group (2010) Pro-atrial natriuretic peptide and pro-vasopressin for predicting short-term and long-term survival in community-acquired pneumonia: results from the German Competence Network CAPNETZ. Thorax 65(3):208–214

    PubMed  Google Scholar 

  89. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, Graff LG, Fine JM, Fine MJ (2005) Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 118(4):384–392

    PubMed  Google Scholar 

  90. Renaud B, Coma E, Labarere J, Hayon J, Roy PM, Boureaux H, Moritz F, Cibien JF, Guérin T, Carré E, Lafontaine A, Bertrand MP, Santin A, Brun-Buisson C, Fine MJ, Roupie E (2007) Routine use of the Pneumonia Severity Index for guiding the site-of-treatment decision of patients with pneumonia in the emergency department: a multicenter, prospective, observational, controlled cohort study. Clin Infect Dis 44(1):41–49

    PubMed  Google Scholar 

  91. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agustí C, Angrill J, García E, Mensa J, Niederman MS, Torres A (2007) Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 132(2):515–522

    PubMed  Google Scholar 

  92. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD, Grayson ML (2008) Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 40(4):293–300

    PubMed  Google Scholar 

  93. Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, Brown GV (2006) A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax 61(5):419–424

    PubMed  CAS  Google Scholar 

  94. Aspa J, Rajas O, de Castro FR (2008) Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother 9(2):229–241

    PubMed  CAS  Google Scholar 

  95. Lynch JP 3rd, Zhanel GG (2005) Escalation of antimicrobial resistance among Streptococcus pneumoniae: implications for therapy. Semin Respir Crit Care Med 26(6):575–616

    PubMed  Google Scholar 

  96. Campbell GD Jr, Silberman R (1998) Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 26(5):1188–1195

    PubMed  Google Scholar 

  97. Clavo-Sánchez AJ, Girón-González JA, López-Prieto D, Canueto-Quintero J, Sánchez-Porto A, Vergara-Campos A, Marín-Casanova P, Córdoba-Doña JA (1997) Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 24(6):1052–1059

    PubMed  Google Scholar 

  98. Vanderkooi OG, Low DE, Green K, Powis JE, McGeer A (2005) Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 40(9):1288–1297

    PubMed  CAS  Google Scholar 

  99. Yu VL, Chiou CC, Feldman C, Ortqvist A, Rello J, Morris AJ, Baddour LM, Luna CM, Snydman DR, Ip M, Ko WC, Chedid MB, Andremont A, Klugman KP (2003) An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 37(2):230–237

    PubMed  CAS  Google Scholar 

  100. File TM Jr (2006) Clinical implications and treatment of multiresistant Streptococcus pneumoniae pneumonia. Clin Microbiol Infect 12(Suppl 3):31–41

    PubMed  CAS  Google Scholar 

  101. Bradley SF (2005) Staphylococcus aureus pneumonia: emergence of MRSA in the community. Semin Respir Crit Care Med 26(6):643–649

    PubMed  Google Scholar 

  102. Drews TD, Temte JL, Fox BC (2006) Community-associated methicillin-resistant Staphylococcus aureus: review of an emerging public health concern. WMJ 105(1):52–57

    PubMed  Google Scholar 

  103. Ebert MD, Sheth S, Fishman EK (2009) Necrotizing pneumonia caused by community-acquired methicillin-resistant Staphylococcus aureus: an increasing cause of “mayhem in the lung”. Emerg Radiol 16:159–162

    PubMed  Google Scholar 

  104. Prevost G, Couppie P, Prevost P, Gayet S, Petiau P, Cribier B, Monteil H, Piemont Y (1995) Epidemiological data on Staphylococcus aureus strains producing synergohymenotropic toxins. J Med Microbiol 42(4):237–245

    PubMed  CAS  Google Scholar 

  105. Nimmo GR, Coombs GW (2008) Community-associated methicillin-resistant Staphylococcus aureus (MRSA) in Australia. Int J Antimicrob Agents 31(5):401–410

    PubMed  CAS  Google Scholar 

  106. Roberts JC, Gulino SP, Peak KK, Luna VA, Sanderson R (2008) Fatal necrotizing pneumonia due to a Panton–Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and Influenza co-infection: a case report. Ann Clin Microbiol Antimicrob 7:5

    PubMed  Google Scholar 

  107. Rougemont AL, Buteau C, Ovetchkine P, Bergeron C, Fournet JC, Bouron-Dal Soglio D (2009) Fatal cases of Staphylococcus aureus pleural empyema in infants. Pediatr Dev Pathol 12(5):390–393

    PubMed  Google Scholar 

  108. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, Torres A (2002) Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 162(16):1849–1858

    PubMed  Google Scholar 

  109. Garau J, Gomez L (2003) Pseudomonas aeruginosa pneumonia. Curr Opin Infect Dis 16(2):135–143

    PubMed  CAS  Google Scholar 

  110. Lim I, Shaw DR, Stanley DP, Lumb R, McLennan G (1989) A prospective hospital study of the aetiology of community-acquired pneumonia. Med J Aust 151(2):87–91

    PubMed  CAS  Google Scholar 

  111. Venkatesan P, Gladman J, Macfarlane JT, Barer D, Berman P, Kinnear W, Finch RG (1990) A hospital study of community acquired pneumonia in the elderly. Thorax 45(4):254–258

    PubMed  CAS  Google Scholar 

  112. Fang GD, Fine M, Orloff J, Arisumi D, Yu VL, Kapoor W, Grayston JT, Wang SP, Kohler R, Muder RR, Yee UC, Rihs JD, Vickers R (1990) New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 69(5):307–316

    CAS  Google Scholar 

  113. Ruiz M, Ewig S, Marcos MA, Martinez JA, Arancibia F, Mensa J, Torres A (1999) Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 160(2):397–405

    PubMed  CAS  Google Scholar 

  114. Liam CK, Lim KH, Wong CM (2001) Community-acquired pneumonia in patients requiring hospitalization. Respirology 6(3):259–264

    PubMed  CAS  Google Scholar 

  115. Tan YK, Khoo KL, Chin SP, Ong YY (1998) Aetiology and outcome of severe community-acquired pneumonia in Singapore. Eur Respir J 12(1):113–115

    PubMed  CAS  Google Scholar 

  116. Marik PE (2000) The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 15(3):85–90

    PubMed  CAS  Google Scholar 

  117. von Baum H, Ewig S, Marre R, Suttorp N, Gonschior S, Welte T, Lück C (2008) Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 46(9):1356–1364

    Google Scholar 

  118. Sopena N, Force L, Pedro-Botet ML, Barrufet P, Sauca G, García-Núñez M, Tolchinsky G, Capdevila JA, Sabrià M (2007) Sporadic and epidemic community legionellosis: two faces of the same illness. Eur Respir J 29(1):138–142

    PubMed  CAS  Google Scholar 

  119. Luna CM, Brea Folco J, Aruj P, Rebora K, Balsebre C, Absi R, Vay C, De Mier C, Famiglietti A (2004) Pneumonia due to Legionella pneumophila. Experience gathered in a University Hospital in Buenos Aires. Medicina (B Aires) 64(2):97–102

    Google Scholar 

  120. Sopena N, Pedro-Botet L, Mateu L, Tolschinsky G, Rey-Joly C, Sabrià M (2007) Community-acquired legionella pneumonia in elderly patients: characteristics and outcome. J Am Geriatr Soc 55(1):114–119

    PubMed  Google Scholar 

  121. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, Schaberg T, Torres A, van der Heijden G, Verheij TJ (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26(6):1138–1180

    PubMed  CAS  Google Scholar 

  122. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, Le Berre MA, Lode H, Winter J, Read RC (2008) Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study—a randomized clinical trial. Clin Infect Dis 46(10):1499–1509

    PubMed  CAS  Google Scholar 

Download references

Transparency declarations

This review was sponsored by Wyeth, which was acquired by Pfizer in October 2009. Dr. Welte was not paid for his participation as an author of this manuscript. Editorial support for the preparation of this manuscript, funded by Pfizer, was provided by Hessamedin Alimohammadi of Upside Endeavors, LLC (Sanatoga, PA).

Author information

Authors and Affiliations

  1. Hannover Medical School, Hannover, Germany

    T. Welte

Authors
  1. T. Welte
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. Welte.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Welte, T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis 31, 33–47 (2012). https://doi.org/10.1007/s10096-011-1272-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-011-1272-4

Keywords

Search

Navigation